Shiva

Nikhil Shiva

Associate
he/him/his
Nikhil Shiva
Boston
+1 617 570 1894

Nikhil Shiva is a corporate associate in Goodwin’s Life Sciences group. Nikhil advises life sciences, healthcare, and technology companies, as well as the investors who back them, across the corporate life cycle, including company formations, venture capital financings, mergers & acquisitions, capital markets transactions, initial public offerings (IPOs), public company reporting, and corporate governance matters. With a background in bioengineering and a master’s degree in bioscience enterprise from the University of Cambridge, Nikhil brings both scientific and commercial fluency to his clients’ platforms and programs. He joined Goodwin in 2023.

Experience

Nikhil represents emerging companies from formation through growth-stage financings and strategic exits and has helped launch more than a dozen new life sciences companies. He also advises public companies on SEC reporting and compliance matters, including Forms 10-K and 10-Q, proxy statements, at-the-market offerings, and Section 16 reporting, and represents venture capital and institutional investors in their portfolio investments.

As a first-year associate, Nikhil was on secondment at a leading life sciences investment fund as part of Goodwin’s Client Immersion Program.

Representative Matters

  • Blueprint Medicines in its sale to Sanofi
  • Centessa Pharmaceuticals in its $250 million follow-on offering and its acquisition by Eli Lilly and Company
  • Freenome in its $330 million deSPAC with Perceptive Capital Solutions Corp.
  • Parabilis Medicines in its $305 million Series F financing, $770.5 million IPO, and $75 million private placement
  • Kardigan in its $254 million Series B financing and $460 million IPO
  • Dren Bio in connection with its sale of DR-0201 to Sanofi
  • Day Zero Diagnostics in its asset sale to bioMérieux
  • RA Capital in its portfolio company investments
  • Wellington Management in its portfolio company investments
  • InTandem Capital in its strategic equity investment in Healthfuse
  • Radial in its $50 million Series A financing
  • Datavolo in its sale to Snowflake
  • PennyMac Financial Services in connection with its private offering of $650 million of senior notes

Credentials

Education

JD2023

Stanford Law School

MPhilBioscience Enterprise2019

University of Cambridge

BS Bioengineering2018

University of Illinois at Urbana-Champaign

(high honors)

Admissions

Bars

  • Massachusetts

Recognition & Awards

Goodwin Pro Bono Star, 2025

Publications

Co-Author, “CRISPR-SKIP: programmable gene splicing with single base editors,” Genome Biol 19, 107, 2018